Cargando…

FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile

FMS-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myeloid leukemia (AML). Approximately 30% of the adult cases harbor an internal tandem duplication (FLT3-ITD) and 5–10% a tyrosine kinase domain (TKD) amino acid substitution (FLT3-TKD). The treatment paradigm of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garciaz, Sylvain, Hospital, Marie-Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869913/ https://www.ncbi.nlm.nih.gov/pubmed/36698434 http://dx.doi.org/10.2147/OTT.S236740

Ejemplares similares

Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia
por: Pazhakh, Vahid, et al.
Publicado: (2011)

Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia
por: Katayama, Kazuhiro, et al.
Publicado: (2018)

Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia
por: Sun, Jie, et al.
Publicado: (2016)

Fms-like tyrosine kinase 3-internal tandem duplications epigenetically activates checkpoint kinase 1 in acute myeloid leukemia cells
por: Zhang, Yudong, et al.
Publicado: (2021)

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance
por: Garciaz, Sylvain, et al.
Publicado: (2021)

Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis
por: Xu, Qingyu, et al.
Publicado: (2021)

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
por: Ruvolo, Peter P., et al.
Publicado: (2017)

Serum soluble FMS-like tyrosine kinase-1 in ectopic pregnancy
por: Selvarajan, Sathya, et al.
Publicado: (2019)

Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia
por: Park, Soojin, et al.
Publicado: (2021)

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
por: Perrone, Salvatore, et al.
Publicado: (2023)

The VEGF Inhibitor Soluble Fms-like Tyrosine Kinase 1 Does Not Promote AKI-to-CKD Transition
por: van Aanhold, Cleo C. L., et al.
Publicado: (2022)

Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3
por: Zeyn, Yanira, et al.
Publicado: (2023)

Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD
por: Zsengellér, Zsuzsanna K., et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Regulation of expression level of fms-like tyrosine kinase-4 is related to osteoclast differentiation
por: Zhu, Yi, et al.
Publicado: (2015)

Fms-like tyrosine kinase 3 is a regulator of the cardiac side population in mice
por: Della Verde, Giacomo, et al.
Publicado: (2021)

Soluble FMS-Like Tyrosine Kinase-1: Role in placenta accreta spectrum disorder
por: Lumbanraja, Sarma, et al.
Publicado: (2022)

The Endothelial Glycocalyx as a Target of Excess Soluble Fms-like Tyrosine Kinase-1
por: Schulz, Annika, et al.
Publicado: (2023)

Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations
por: Abruzzese, Elisabetta, et al.
Publicado: (2020)

FMS-like tyrosine kinase 3 is required for dendritic cell development in peripheral lymphoid tissues
por: Waskow, Claudia, et al.
Publicado: (2008)

Fms-Like Tyrosine Kinase 3 Ligand Controls Formation of Regulatory T Cells in Autoimmune Arthritis
por: Svensson, Mattias N. D., et al.
Publicado: (2013)

Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia
por: Sánchez-Aranguren, Lissette C., et al.
Publicado: (2018)

Soluble Fms-Like Tyrosine Kinase-1 Is A Marker of Endothelial Dysfunction During Sepsis
por: Greco, Marilena, et al.
Publicado: (2018)

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
por: Hasegawa, Hiroko, et al.
Publicado: (2020)

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
por: Bavaro, Luana, et al.
Publicado: (2019)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
por: Ke, Yi-Yu, et al.
Publicado: (2015)

Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia
por: Perrotti, Danilo, et al.
Publicado: (2012)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia
por: Ciaffaglione, Valeria, et al.
Publicado: (2022)

Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
por: Kim, Shin-Young, et al.
Publicado: (2008)

Variability in mRNA expression of fms-like tyrosine kinase-1 variants in normal and preeclamptic placenta
por: Surmon, Laura, et al.
Publicado: (2014)

FMS-Like Tyrosine Kinase 3 Ligand Treatment Does Not Ameliorate Experimental Rapidly Progressive Glomerulonephritis
por: Ghali, Joanna R., et al.
Publicado: (2015)

Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model
por: Tsuzuki, Hirofumi, et al.
Publicado: (2022)

2-Methoxyestradiol combined with ascorbic acid facilitates the apoptosis of chronic myeloid leukemia cells via the microRNA-223/Fms-like tyrosine kinase 3/phosphatidylinositol-3 kinase/protein kinase B axis
por: Zhang, Suwei, et al.
Publicado: (2022)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics
por: Rezaei, Narges, et al.
Publicado: (2017)

Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS‐like tyrosine kinase 3‐internal tandem duplication with central nervous system involvement
por: Suga, Makiko, et al.
Publicado: (2022)

Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review
por: Jacobs, Marni, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_brnuacc95namhltokbo8al046e